Terms: = Lung cancer AND HNRNPA2B1, ENSG00000122566, SNRPB1, RNPA2, HNRPB1, HNRPA2, HNRNPB1, HNRNPA2, 3181 AND Treatment
14 results:
1. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
Wang K; Du R; Myall NJ; Lewis WE; Uy N; Hong L; Skoulidis F; Byers LA; Tsao A; Cascone T; Pozadzides J; Tu J; Negrao MV; Gibbons DL; Park K; Rinsurongkawong W; Lee JJ; Gandara D; Behl D; Shu CA; Riess JW; Baik C; Wakelee HA; Vaporciyan AA; Heymach JV; Zhang J; Le X
J Thorac Oncol; 2024 Mar; 19(3):500-506. PubMed ID: 38012986
[TBL] [Abstract] [Full Text] [Related]
2. RNA-binding protein-regulated fibronectin is essential for EGFR-activated metastasis of head and neck squamous cell carcinoma.
Shieh JM; Chang TW; Wang JH; Liang SP; Kao PL; Chen LY; Yen CJ; Chen YJ; Chang WC; Chen BK
FASEB J; 2023 Oct; 37(10):e23206. PubMed ID: 37718485
[TBL] [Abstract] [Full Text] [Related]
3. N6-methyladenosine in hematological malignancies: a concise review.
Wang WJ; Xu TT; Bao J
Curr Opin Hematol; 2023 Jan; 30(1):4-13. PubMed ID: 36165537
[TBL] [Abstract] [Full Text] [Related]
4. hnrnpa2b1 inhibited SFRP2 and activated Wnt-β/catenin via m6A-mediated miR-106b-5p processing to aggravate stemness in lung adenocarcinoma.
Rong L; Xu Y; Zhang K; Jin L; Liu X
Pathol Res Pract; 2022 May; 233():153794. PubMed ID: 35364458
[TBL] [Abstract] [Full Text] [Related]
5. Heterogeneous nuclear ribonucleoprotein A2/B1 regulates the ERK and p53/HDM2 signaling pathways to promote the survival, proliferation and migration of non‑small cell lung cancer cells.
Kim MK; Choi MJ; Lee HM; Choi HS; Park YK; Ryu CJ
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34109989
[TBL] [Abstract] [Full Text] [Related]
6. Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer.
Lei Y; Guo W; Chen B; Chen L; Gong J; Li W
Oncol Rep; 2018 Dec; 40(6):3438-3446. PubMed ID: 30542738
[TBL] [Abstract] [Full Text] [Related]
7. Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
Ouyang X; Shi M; Jie F; Bai Y; Shen P; Yu Z; Wang X; Huang C; Tao M; Wang Z; Xie C; Wu Q; Shu Y; Han B; Zhang F; Zhang Y; Hu C; Ma X; Liang Y; Wang A; Lu B; Shi Y; Chen J; Zhuang Z; Wang J; Huang J; Wang C; Bai C; Zhou X; Li Q; Chen F; Yu H; Feng J
Invest New Drugs; 2018 Apr; 36(2):315-322. PubMed ID: 29134432
[TBL] [Abstract] [Full Text] [Related]
8. Epidemiological evaluation of the outcomes after video-assisted thoracoscopic talcage in neoplastic pleurisy.
Bosînceanu M; Sandu C; Roată CE; Ionescu LR; Miron L
Rev Med Chir Soc Med Nat Iasi; 2015; 119(1):112-8. PubMed ID: 25970953
[TBL] [Abstract] [Full Text] [Related]
9. Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnrnpa2b1) in tumour tissue and blood samples from patients diagnosed with lung cancer.
Dowling P; Pollard D; Larkin A; Henry M; Meleady P; Gately K; O'Byrne K; Barr MP; Lynch V; Ballot J; Crown J; Moriarty M; O'Brien E; Morgan R; Clynes M
Mol Biosyst; 2015 Mar; 11(3):743-52. PubMed ID: 25483567
[TBL] [Abstract] [Full Text] [Related]
10. Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer.
Han Y; Yu DP; Zhou SJ; Song XY; Li YS; Xiao N; Liu ZD; Sun XJ; Zhao QY; Liu SK
Genet Mol Res; 2014 Oct; 13(4):8913-24. PubMed ID: 25366782
[TBL] [Abstract] [Full Text] [Related]
11. Survival following sublobar resection for early-stage non-small cell lung cancer with or without adjuvant external beam radiation therapy: a population-based study.
Rineer J; Schreiber D; Katsoulakis E; Nabhani T; Han P; Lange C; Choi K; Rotman M
Chest; 2010 Feb; 137(2):362-8. PubMed ID: 19749007
[TBL] [Abstract] [Full Text] [Related]
12. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
[TBL] [Abstract] [Full Text] [Related]
13. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the cancer and Leukemia Group B.
Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
[TBL] [Abstract] [Full Text] [Related]
14. Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications.
Niklinski J; Niklinska W; Chyczewski L; Becker HD; Pluygers E
Eur J Cancer Prev; 2001 Jun; 10(3):213-26. PubMed ID: 11432708
[TBL] [Abstract] [Full Text] [Related]
